Apelin: A Potential Biomarker for Early Diagnosis of Coronary Artery Disease in COPD Patients

Aksakal A., Kerget B., Topal B. N., Laloğlu E., Sağlam L.

TÜSAD, SOLUNUM 2024, Antalya, Türkiye, 20 - 24 Kasım 2024, cilt.1, ss.1290-1291, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 1
  • Basıldığı Şehir: Antalya
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.1290-1291
  • Atatürk Üniversitesi Adresli: Evet

Özet

Abstract:

Background: Apelins, adipokines with anti-inflammatory, vasodilatory, and antiatherosclerotic properties, are implicated in various chronic diseases, including chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD). This study investigates the potential of apelin as a biomarker for the early detection and management of CAD in COPD patients.

Methods: A total of 73 stable COPD patients and 35 healthy controls matched for age and gender were included. COPD patients were divided into two groups: those without CAD (Group 1) and those with CAD (Group 2). Serum levels of apelin isoforms (12, 13, 17, and 36) were measured using ELISA.

Results: Apelin levels were significantly lower in COPD patients compared to controls (p<0.001). Among COPD patients, those with CAD had lower apelin levels than those without CAD (p=0.005 for apelin 12; p<0.001 for apelin 13, 17, and 36). ROC analysis demonstrated that apelin 13 and 36 had high sensitivity and specificity for predicting CAD in COPD patients. Apelin 13 and 36 were positively correlated with ejection fraction (EF) (R=0.43, p=0.01; R=0.4, p=0.01), and apelin 12 was correlated with FEV1 and FVC (R=0.24, p=0.04; R=0.27, p=0.02).

Conclusion: CAD in COPD patients is often underdiagnosed despite its significant impact on prognosis. Serum apelin levels, particularly apelin 13 and 36, may serve as valuable biomarkers for the early diagnosis and management of CAD in COPD patients. Key Words: Apelin, COPD, Coronary Artery Disease, Biomarker, Adipokine